Significant condition. by Junxia Zhou (14381598)

“…BET and SEM analyses demonstrated that the specific surface area and porosity (most probable pore size) gradually decreased over time. At various ages, mesopores (cumulative pore diameter, median pore diameter) initially increased and then decreased. …”

Results of significance for regression factors. by Junxia Zhou (14381598)

“…BET and SEM analyses demonstrated that the specific surface area and porosity (most probable pore size) gradually decreased over time. At various ages, mesopores (cumulative pore diameter, median pore diameter) initially increased and then decreased. …”

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. by William C. Barley (8915282)

Subjects:

The significant decrease in GLT-1 levels observed in the nucleus accumbens of rats that had consumed morphine for fifty-six days was completely reversed by the co-administration of NAC (40 mg/kg/day, i.p.) and ibudilast (7.5 mg/kg/day, i.p.). by María Elena Quintanilla (8068691)

Results of the generalized linear mixed model (GLMM) for correct responses in the speech recognition task. by Elena Bolt (20396190)

Subjects:

Results of linear mixed models (LMMs) on linguistic timescale tracking for the phrase, word, syllable, and phoneme rates. by Elena Bolt (20396190)

Subjects:

Results of the linear models for the amplitudes (in <i>μ</i>V) of the components P1, N1, P2, and N400. by Elena Bolt (20396190)

Subjects:

The results of linear mixed model. by Soheila Qanbari (20455173)

Subjects:

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

Subjects:

Statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

GLM models for predictors of monthly HIV costs. by Drew B. Cameron (10687420)

Subjects:

Median cost (USD) per visit breakdown. by Drew B. Cameron (10687420)

Subjects:

Descriptive statistics (means) for full sample and by lockdown status. by Drew B. Cameron (10687420)

Subjects:

Study sites and number of participants enrolled in the KAP and OOP surveys. by Drew B. Cameron (10687420)

Subjects:

Average cost per visit for HIV and HTN care (absolute vs. relative contributions). by Drew B. Cameron (10687420)

Subjects:

GLM models for predictors of monthly HTN care costs. by Drew B. Cameron (10687420)

Subjects:

Median monthly care costs, projected visits, and hospitalization costs. by Drew B. Cameron (10687420)

Subjects:

Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)